Are methotrexate side effects more severe in children?

How do side effects differ in pediatric versus adult patients?

Methotrexate dosing in children often follows weight-based calculations, which can lead to more pronounced short-term effects on bone marrow and digestive tract. Pediatric patients show higher rates of gastrointestinal upset and temporary drops in blood counts compared with fixed-dose regimens in older patients. These differences arise mainly from faster metabolism and relative immaturity of organ systems.

What long-term risks matter most for children?

Long-term follow-up data indicate that methotrexate does not permanently impair linear growth when used intermittently at low doses. The drug remains safe for juvenile idiopathic arthritis and acute lymphoblastic leukemia protocols, though liver fibrosis and lung toxicity require ongoing monitoring with imaging and blood tests. Patients treated for extended periods may also show subtle cognitive changes that are still under study.

When does toxicity appear and how is it reversed?

Bone-marrow suppression and mucositis surface within 2–5 days after a dose. Rescue with folinic acid (leucovorin) reverses most acute toxicity if administered 24–48 hours later. Parents should watch for fever, bruising, or severe nausea, which are markers of serious complications that can lead to dose adjustment or temporary suspension.

Why are companies challenging this patent?

Patent disputes on methotrexate formulations focus on once-weekly oral or subcutaneous delivery methods rather than the generic active ingredient itself. Companies seek approval for new routes that improve compliance in children, thereby gaining market exclusivity for those specific presentations.